Last reviewed · How we verify
BNT162b2 (bnt162b2)
BNT162b2, marketed by Pfizer, is an mRNA-based vaccine for COVID-19 prevention, currently generating significant revenue as a leading product in the global vaccine market. Its key strength lies in its robust mechanism of action, which has been validated through widespread use and efficacy in preventing COVID-19. The primary risk is the competitive landscape, particularly from ChAdOx1 nCoV-19 by Oxford–AstraZeneca, which induces higher levels of specific T cells, and mRNA-1273 by Moderna, known for inducing higher antibody titers.
At a glance
| Generic name | bnt162b2 |
|---|---|
| Sponsor | Pfizer |
| Drug class | vaccine |
| Target | SARS-CoV-2 virus |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- COVID-19 prevention
- COVID-19 treatment
Common side effects
- Injection site pain
- Fatigue
- Myalgia
- Headache
- Chills
- Pyrexia
- Lymphadenopathy
- Pain
- Injection site pain (PAIN)
- Fatigue (FATIGUE)
- Vaccination site pain
- Headache (HEADACHE)
Drug interactions
- Warfarin
- Corticosteroids
- Live vaccines
- Immunosuppressants
- Interferons
- Thalidomide
- Sipuleucel-T
- BCG vaccine
- Typhoid vaccine
- Rabies vaccine
- Influenza vaccine
- Hepatitis A vaccine
Key clinical trials
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population (PHASE2)
- Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |